Hexima Limited (HXL.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 248.67 Thousand AUD | 42.55% |
| 2023 | 174.44 Thousand AUD | -97.18% |
| 2022 | 6.18 Million AUD | 11.9% |
| 2021 | 5.52 Million AUD | 63.16% |
| 2020 | 3.38 Million AUD | -13.82% |
| 2019 | 3.93 Million AUD | 94.59% |
| 2018 | 2.02 Million AUD | 8.12% |
| 2017 | 1.86 Million AUD | -7.14% |
| 2016 | 2.01 Million AUD | 10.66% |
| 2015 | 1.81 Million AUD | -8.1% |
| 2014 | 1.97 Million AUD | 30.82% |
| 2013 | 1.51 Million AUD | 0.0% |
| 2010 | 2.63 Million AUD | 1.95% |
| 2009 | 2.58 Million AUD | -11.5% |
| 2008 | 2.91 Million AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 105.9 Thousand AUD | 0.0% |
| 2024 FY | 248.67 Thousand AUD | 42.55% |
| 2024 Q4 | 248.67 Thousand AUD | 0.0% |
| 2024 Q1 | 105.9 Thousand AUD | -98.39% |
| 2023 Q2 | 1.16 Million AUD | 0.0% |
| 2023 Q1 | 1.16 Million AUD | -81.11% |
| 2023 FY | 174.44 Thousand AUD | -97.18% |
| 2023 Q3 | 174.44 Thousand AUD | -85.08% |
| 2023 Q4 | 6.59 Million AUD | 3680.13% |
| 2022 FY | 6.18 Million AUD | 11.9% |
| 2022 Q3 | 6.18 Million AUD | -3.68% |
| 2022 Q4 | 6.18 Million AUD | 0.0% |
| 2022 Q1 | 6.42 Million AUD | 16.18% |
| 2022 Q2 | 6.42 Million AUD | 0.0% |
| 2021 Q4 | 5.52 Million AUD | 41.32% |
| 2021 Q1 | 2.2 Million AUD | -66.3% |
| 2021 Q2 | 3.79 Million AUD | 71.87% |
| 2021 Q3 | 3.91 Million AUD | 3.21% |
| 2021 FY | 5.52 Million AUD | 63.16% |
| 2020 Q4 | 6.54 Million AUD | 0.0% |
| 2020 Q3 | 6.54 Million AUD | 30.6% |
| 2020 FY | 3.38 Million AUD | -13.82% |
| 2020 Q2 | 5.01 Million AUD | 0.0% |
| 2020 Q1 | 5.01 Million AUD | 27.45% |
| 2019 FY | 3.93 Million AUD | 94.59% |
| 2019 Q4 | 3.93 Million AUD | 0.0% |
| 2019 Q2 | 1.06 Million AUD | 0.0% |
| 2019 Q1 | 1.06 Million AUD | -47.42% |
| 2019 Q3 | 3.93 Million AUD | 270.08% |
| 2018 FY | 2.02 Million AUD | 8.12% |
| 2018 Q2 | 2.79 Million AUD | 0.0% |
| 2018 Q1 | 2.79 Million AUD | 49.7% |
| 2018 Q3 | 2.02 Million AUD | -27.78% |
| 2018 Q4 | 2.02 Million AUD | 0.0% |
| 2017 Q2 | 1.89 Million AUD | 0.0% |
| 2017 FY | 1.86 Million AUD | -7.14% |
| 2017 Q4 | 1.86 Million AUD | 0.0% |
| 2017 Q1 | 1.89 Million AUD | -5.78% |
| 2017 Q3 | 1.86 Million AUD | -1.44% |
| 2016 Q2 | 2.07 Million AUD | 0.0% |
| 2016 Q4 | 2.01 Million AUD | 0.0% |
| 2016 Q3 | 2.01 Million AUD | -2.93% |
| 2016 FY | 2.01 Million AUD | 10.66% |
| 2016 Q1 | 2.07 Million AUD | 14.0% |
| 2015 FY | 1.81 Million AUD | -8.1% |
| 2015 Q3 | 1.81 Million AUD | -23.8% |
| 2015 Q2 | 2.38 Million AUD | 0.0% |
| 2015 Q4 | 1.81 Million AUD | 0.0% |
| 2015 Q1 | 2.38 Million AUD | 20.6% |
| 2014 FY | 1.97 Million AUD | 30.82% |
| 2014 Q4 | 1.97 Million AUD | 0.0% |
| 2014 Q1 | 1.32 Million AUD | -12.39% |
| 2014 Q3 | 1.97 Million AUD | 49.32% |
| 2014 Q2 | 1.32 Million AUD | 0.0% |
| 2013 Q4 | 1.51 Million AUD | 0.0% |
| 2013 FY | 1.51 Million AUD | 0.0% |
| 2013 Q1 | 1.48 Million AUD | 0.0% |
| 2013 Q2 | 1.48 Million AUD | 0.0% |
| 2013 Q3 | 1.51 Million AUD | 1.75% |
| 2010 FY | 2.63 Million AUD | 1.95% |
| 2010 Q4 | 2.63 Million AUD | 0.0% |
| 2009 Q4 | 2.58 Million AUD | 0.0% |
| 2009 FY | 2.58 Million AUD | -11.5% |
| 2008 Q4 | 2.91 Million AUD | 0.0% |
| 2008 FY | 2.91 Million AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AdAlta Limited | 3.54 Million AUD | 92.98% |
| Biome Australia Limited | 5.37 Million AUD | 95.372% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 99.443% |
| Biotron Limited | 737.5 Thousand AUD | 66.282% |
| Acrux Limited | 5.68 Million AUD | 95.627% |
| Alterity Therapeutics Limited | 5.42 Million AUD | 95.417% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | 93.337% |
| BTC Health Limited | 203.94 Thousand AUD | -21.928% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | 98.058% |
| CSL Limited | 27.88 Billion AUD | 99.999% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | 97.015% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | 99.115% |
| Immutep Limited | 10.97 Million AUD | 97.735% |
| Memphasys Limited | 5.59 Million AUD | 95.553% |
| Neuren Pharmaceuticals Limited | 42.76 Million AUD | 99.418% |
| Noxopharm Limited | 1.28 Million AUD | 80.703% |
| Prescient Therapeutics Limited | 2.32 Million AUD | 89.307% |
| Race Oncology Limited | 1.91 Million AUD | 87.024% |
| Starpharma Holdings Limited | 8.69 Million AUD | 97.141% |
| Tissue Repair Ltd | 1.35 Million AUD | 81.592% |
| EZZ Life Science Holdings Limited | 4.22 Million AUD | 94.12% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | 18.96% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | 32.508% |
| Zelira Therapeutics Limited | 9.35 Million AUD | 97.342% |
| Patrys Limited | 691.36 Thousand AUD | 64.032% |
| Orthocell Limited | 22.08 Million AUD | 98.874% |
| Imugene Limited | 33.14 Million AUD | 99.25% |
| PYC Therapeutics Limited | 10.18 Million AUD | 97.558% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | 84.706% |
| Cynata Therapeutics Limited | 1.17 Million AUD | 78.765% |
| Arovella Therapeutics Limited | 2.05 Million AUD | 87.909% |
| Nanollose Limited | 465.64 Thousand AUD | 46.596% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | 42.388% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -190.221% |
| Amplia Therapeutics Limited | 3.42 Million AUD | 92.743% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | 76.218% |
| Nyrada Inc. | 855.63 Thousand AUD | 70.937% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 99.9% |
| Dimerix Limited | 13.89 Million AUD | 98.21% |
| PharmAust Limited | 896.6 Thousand AUD | 72.265% |
| AnteoTech Limited | 4.07 Million AUD | 93.898% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | 93.062% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | 98.435% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | 73.589% |
| Actinogen Medical Limited | 1.61 Million AUD | 84.606% |
| Immuron Limited | 2.84 Million AUD | 91.246% |
| Argenica Therapeutics Limited | 2.42 Million AUD | 89.753% |